RxDoctor Payments DataLook up a doctor →

Apoor Patel, MD

Clinical Cardiac Electrophysiology · Sugar Land, TXNPI 1104877687

Payments from drug & device makers

$287,231in general payments, 2019–2025

Across 816 payments — averaging $352.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$159K
  • Medical Device Business Services, Inc.$60K
  • Biosense Webster, Inc.$53K
  • Abbott$7K
  • Medtronic$3K
  • Atricure, Inc.$1K
  • plus $3K from 27 others

What the payments were for

  • Consulting fees$136,52748%
  • Speaking & faculty fees$99,70035%
  • Travel & lodging$27,2309%
  • Food & beverage$23,6798%
  • Education$730%
  • Entertainment$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$287,231 in reported general payments places this provider in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$595,016
Medicare patients
1,085
Services billed
5,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$286,115
XareltoRivaroxaban182$183,497
MultaqDronedarone Hcl15$26,224
Amiodarone Hcl162$5,162
Metoprolol Succinate212$3,134
Flecainide Acetate77$2,463
Mexiletine Hcl25$1,792
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$653
SotalolSotalol Hcl21$577
Digoxin20$498
Metoprolol Tartrate46$341
ClopidogrelClopidogrel Bisulfate40$338
Minocycline Hcl37$295
Carvedilol39$200
Colchicine13$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$212$286,115257 claims
Johnson & JohnsonXarelto$200$183,497182 claims
Sanofi-aventis U.S. LLCMultaq$86$26,22415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →